Bausch + Lomb

362 articles about Bausch + Lomb

• South Korea's MFDS Approves LUMIFY® Eye Drops

  1/21/2021

   Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that LUMIFY ® (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea .

• Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium

  1/20/2021

  Bausch + Lomb Will Also Host Presentation on Technologies that Can Help Create Efficiencies in Fitting Zenlens™ Scleral Lenses on Patients

• Bausch Health Announces Investigational In Vitro Data Indicating Complete Inactivation Of SARS-CoV-2 With LUMIFY® And BESIVANCE® Eye Drops Preserved With Benzalkonium Chloride

  11/16/2020

  Bausch Health Companies Inc. and Bausch + Lomb, its leading global eye health business, announced the results of new investigational in vitro data showing that two benzalkonium chloride preserved eye drops, LUMIFY® redness reliever eye drops and BESIVANCE® 0.6%, indicated complete inactivation of Severe Acute Respiratory Syndrome-related Coronavirus 2.

• Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Materials Recycled Through One By One Recycling Program

  11/12/2020

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that its exclusive ONE by ONE Recycling program has recycled nearly 27 million used contact lenses, top foils and blister packs since launching in November 2016.

• Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses

  10/27/2020

  First Preloaded Toric Available in the United States and Monofocal Option Combine Consistent IOL Delivery with Outstanding Visual Outcomes of enVista®

• Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens

  10/15/2020

  Bausch Health Companies Inc. and Bausch + Lomb, its leading global eye health business, along with BHVI, an Australian not-for-profit organization with an international focus on vision research, announced that an affiliate of Bausch Health has acquired an exclusive license for a myopia control contact lens design developed by BHVI.

• Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12

  10/12/2020

  Bausch Health Companies Inc., Bausch + Lomb, and Eyenovia, Inc. announced that an affiliate of Bausch Health has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12.

• Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented On Bausch + Lomb Infuse™ Silicone Hydrogel Daily Disposable Contact Lenses During The American Academy Of Optometry Annual Meeting

  10/6/2020

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that three poster presentations will feature the company's new silicone hydrogel daily disposable contact lens, Bausch + Lomb INFUSE™, during the virtual American Academy of Optometry Annual Meeting.

• Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List

  10/1/2020

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that BASES, a Nielsen Global Consumer business division, has named LUMIFY® redness reliever eye drops to its 2020 U.S. BASES Top 25 Breakthrough Innovations List in the "Superstar" category for its success in driving sales and category growth.

• Australia's TGA Approves BAUSCH + LOMB ULTRA® ONE DAY Silicone Hydrogel Daily Disposable Contact Lenses

  8/18/2020

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that it has received approval from Australia's Therapeutic Goods Administration for the supply of BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses.

• Bausch + Lomb Launches Innovative Bausch + Lomb INFUSE™ Silicone Hydrogel (SiHy) Daily Disposable Contact Lenses

  8/17/2020

  Next Generation Material Infused with Proprietary ProBalance Technology™ to Help Maintain Ocular Surface Homeostasis and Help Reduce Contact Lens Dryness, Which Affects More Than Half of Lens Wearers in the United States

• Health Canada Approves BAUSCH + LOMB ULTRA ONE DAY® Silicone Hydrogel Daily Disposable Contact Lenses

  8/11/2020

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that it has received approval from Health Canada for the sale of BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses.

• BAUSCH + LOMB ULTRA® Silicone Hydrogel Contact Lenses Receive Approval In China

  6/17/2020

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that BAUSCH + LOMB ULTRA® monthly silicone hydrogel contact lenses have received approval from the National Medical Products Administration in China.

• FDA Provides 510(k) Clearance For BAUSCH + LOMB INFUSE™ Daily Disposable Silicone Hydrogel (SiHy Daily) Contact Lenses

  6/4/2020

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that it has received 510 clearance from the U.S. Food and Drug Administration for BAUSCH + LOMB INFUSE™ daily disposable silicone hydrogel contact lenses.

• Bausch + Lomb Announces The European Launch Of LuxSmart™ And LuxGood™ Preloaded Intraocular Lenses

  5/27/2020

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the European launch of the company's first Extended Depth of Focus intraocular lens, LuxSmart™, and a new monofocal IOL, LuxGood™.

• Bausch + Lomb Announces Publication Of 10-Year Armor Study Results On Ocular Antibiotic Resistance In JAMA Ophthalmology

  4/14/2020

  Surveillance Data Demonstrates Nationwide Prevalence of Antibiotic Resistant Bacteria Common in Eye Infections

• 

  Biopharma Update on the Novel Coronavirus: April 13

  4/13/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 13, 2020.

• Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2019 Results And Provides 2020 Guidance

  2/19/2020

  LAVAL, Quebec , Feb. 19, 2020 /PRNewswire/ --  Fourth-Quarter 2019 Financial Results Revenues of $2.224 Billion GAAP Cash Generated from Operations of $234 Million GAAP Net Loss of $1.516 Billion Adjusted EBITDA (non-GAAP) 1 of $898 Million Full-Year 2019 Financial Results Revenues of $8.601 Billion GAAP Cash Generated from Operat

• Bausch + Lomb And Prevent Blindness Join Together To Raise Awareness And Provide Educational Resources For February's Age-Related Macular Degeneration Awareness Month

  2/3/2020

  Organizations Launch Social Media Campaign and Offer SightMatters.com to Provide People with AMD and Caregivers with Educational Information, AMD Action Plan and More

• Bausch + Lomb and TerraCycle Partner to Launch Canada's First and Only Contact Lens Recycling Program

  1/27/2020

  Contact Lens Wearers Can Now Recycle Their Contact Lenses and Blister Packs